Truist Financial Raises Lantheus (NASDAQ:LNTH) Price Target to $127.00

Lantheus (NASDAQ:LNTH) had its price objective upped by Truist Financial from $120.00 to $127.00 in a research note released on Thursday morning,Benzinga reports. The brokerage currently has a buy rating on the medical equipment provider’s stock.

Several other research firms have also issued reports on LNTH. The Goldman Sachs Group assumed coverage on Lantheus in a research note on Wednesday, December 18th. They set a “buy” rating and a $143.00 target price on the stock. StockNews.com cut shares of Lantheus from a “buy” rating to a “hold” rating in a research report on Thursday, November 21st. Finally, JMP Securities reaffirmed a “market outperform” rating and set a $112.00 price objective on shares of Lantheus in a research report on Tuesday, January 14th. One research analyst has rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $132.86.

Lantheus Stock Performance

LNTH opened at $91.49 on Thursday. The business’s 50 day moving average price is $89.80 and its 200 day moving average price is $96.75. The stock has a market capitalization of $6.36 billion, a PE ratio of 15.22 and a beta of 0.44. Lantheus has a one year low of $56.44 and a one year high of $126.89.

Lantheus (NASDAQ:LNTH) last announced its quarterly earnings results on Thursday, February 27th. The medical equipment provider reported $1.34 EPS for the quarter, missing the consensus estimate of $1.57 by ($0.23). The business had revenue of $391.11 million during the quarter, compared to analyst estimates of $376.61 million. Lantheus had a net margin of 28.57% and a return on equity of 44.29%. As a group, equities research analysts forecast that Lantheus will post 6.01 earnings per share for the current fiscal year.

Insider Buying and Selling at Lantheus

In related news, Director James H. Thrall sold 1,000 shares of the company’s stock in a transaction on Wednesday, January 15th. The shares were sold at an average price of $94.76, for a total value of $94,760.00. Following the completion of the sale, the director now owns 33,207 shares in the company, valued at $3,146,695.32. This represents a 2.92 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 1.50% of the stock is owned by company insiders.

Institutional Investors Weigh In On Lantheus

A number of institutional investors and hedge funds have recently made changes to their positions in LNTH. Janus Henderson Group PLC raised its stake in Lantheus by 72.7% during the 4th quarter. Janus Henderson Group PLC now owns 6,198,689 shares of the medical equipment provider’s stock valued at $554,583,000 after acquiring an additional 2,610,118 shares during the last quarter. Farallon Capital Management LLC raised its stake in shares of Lantheus by 79.9% during the fourth quarter. Farallon Capital Management LLC now owns 5,316,227 shares of the medical equipment provider’s stock worth $475,590,000 after purchasing an additional 2,361,000 shares during the last quarter. T. Rowe Price Investment Management Inc. lifted its holdings in shares of Lantheus by 40.5% during the fourth quarter. T. Rowe Price Investment Management Inc. now owns 1,509,332 shares of the medical equipment provider’s stock worth $135,025,000 after purchasing an additional 435,445 shares during the period. Raymond James Financial Inc. purchased a new position in Lantheus in the 4th quarter valued at $36,183,000. Finally, Groupama Asset Managment acquired a new position in Lantheus in the 3rd quarter valued at $439,000. 99.06% of the stock is owned by hedge funds and other institutional investors.

About Lantheus

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.